pdf   xlsx method abbreviations

metastatic/advanced RCC (mRCC) - 2nd line (L2), atezolizumab based treatment , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.94 [0.70, 1.27]< 10%1 study (1/-)65.8 %NAnot evaluable crucial-
progression or deaths (PFS) 1.03 [0.83, 1.28]< 10%1 study (1/-)39.5 %NAnot evaluable important-

safety endpoints 00

AE (grade 3-4) 1.29 [0.90, 1.85]< 10%1 study (1/-)8.2 %NAnot evaluable non important-
AE leading to death (grade 5) 1.90 [0.83, 4.35]< 10%1 study (1/-)6.4 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 4.56 [2.23, 9.33]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
SAE (any grade) 1.90 [1.33, 2.71]< 10%1 study (1/-)0.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons